The Anti-Siglec-H antibody reacts with the 34 kDa mouse sialic acid-binding immunoglobulin-like lectin (Siglec) H. Siglec-H is specifically expressed on mouse plasmacytoid dendritic cells1 - a subset of CD11c+ dendritic cells detected at low frequency in all lymphoid tissues, peripheral blood, and some non-lymphoid tissues. Binding of antibodies to Siglec-H inhibits type I interferon production, which can be induced in plasmacytoid dendritic cells by DNA and RNA viruses.2,3 - USA
One hundred and ninety-four adult patients admitted to a Department of Internal Medicine at a tertiary hospital with suspected community acquired infections. Daily blood sampling for sCD163 analysis was performed for up to 5 days. Laboratory analyses were performed with a sandwich ELISA using polyclonal rabbit anti-CD163 as the catching antibody and monoclonal anti-CD163 as the secondary antibody. The patients were classified according to SIRS criteria. The patients were divided in the following groups: patients with no proven infection (n = 67, control group), patients with possible infection (n = 21, not included in analysis), patients with proven infection without SIRS (n = 25), patients with sepsis (n = 52), patients with severe sepsis (n = 29). Only one patient had septic shock. Twelve patients had bacteraemia. Demographic data, comorbidity, microbiological aetiology, biochemical parameters, focus of infection, severity score and mortality on day 28 were recorded. ...
PARIS, Oct. 17 -- Alcatel said it has received a contract to provide equipment to Taiwans Chunghwa Telecom Co. Ltd. in a deal worth over $52 million.
In this report, we show that blockade of CSF1/CSF1R signaling in pancreatic tumors depletes CD206Hi TAMs and reprograms remaining macrophages to support antitumor immunity. The blockade alone modestly enhances antitumor IFN responses, promotes CTL infiltration, and slows tumor progression. However, the therapeutic effect is limited by the induction of T-cell checkpoint molecules, including PDL1 on tumor cells and CTLA4 on T cells. Addition of the CSF1/CSF1R blockade markedly improved the efficacy of αPD1 and αCTLA4 checkpoint immunotherapy and led to the regression of even well-established PDAC tumors. These data suggest that CSF1/CSF1R signaling may be an effective therapeutic target to reprogram the immunosuppressive microenvironment of human PDAC tumors and enhance the efficacy of immunotherapy.. Recent data from several groups suggest that inhibition of CSF1R signaling alters the immunologic responses of tumor-infiltrating macrophages in several cancer types (10-12, 31-33). Mok and ...
CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies; these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia ...
Clone REA812 recognizes the human CD163 antigen, a single-chain transmembrane protein also known as hemoglobin scavenger receptor or M130. It is expressed by mature tissue macrophages and peripheral blood monocytes. The expression of CD163 is up-regulated in vitro and in vivo by anti-inflammatory mediators such as interleukin 10 (IL-10) and (gluco)corticosteroid and is shed to blood upon inflammatory activation of macrophages. CD163 functions as a high affinity scavenger receptor for the complex of haemoglobin and haptoglobin. Depending on the ligand, crosslinking of CD163 initiates signal transduction leading to the production of proinflammatory cytokines Il-1ß, IL-6, and GM-CSF or the anti-inflammatory cytokine IL-10. Additional information: Clone REA812 displays negligible binding to Fc receptors. - Latvija
Rabbit polyclonal antibody raised against synthetic peptide of MNDA. A synthetic peptide corresponding to MNDA. (PAB25135) - Products - Abnova
Macrophage Marker Antibodies available through Novus Biologicals. Browse our Macrophage Marker Antibody catalog backed by our Guarantee+.
F4/80 -----Original Message----- From: [email protected] [mailto:[email protected]]On Behalf Of GT Hebert Sent: 11 July 2005 17:30 To: [email protected] Subject: [Histonet] Macrophage marker mouse tissue Hello, I am in need of a good macrophage marker on FFPE tissue. I will be using it on mouse tissue... mainly the heart (but other tissues may be included). So far I have looked into a number of antibodies (CD68, Mac-2) but can never be certain which one to choose. Thank you in advance for your help. Sincerely, Gustave Gustave Hebert, HT (ASCP) Scientist II Wyeth Research Cardiovascular and Metabolic Diseases Cambridge MA --------------------------------- Sell on Yahoo! Auctions - No fees. Bid on great items. _______________________________________________ Histonet mailing list [email protected] http://lists.utsouthwestern.edu/mailman/listinfo/histonet _______________________________________________ Histonet mailing ...
Macrophage Marker products available through Novus Biologicals. Browse our Macrophage Marker product catalog backed by our Guarantee+.
爱必信(上海)生物科技有限公司专业生产(供应)销售Siglec-3/CD33 (C-6His),欢迎您来电咨询Siglec-3/CD33 (C-6His)的详细信息!
爱必信(上海)生物科技有限公司专业生产(供应)销售Siglec-3/CD33 (C-6His),欢迎您来电咨询Siglec-3/CD33 (C-6His)的详细信息!
High-quality Siglec-6 proteins from ACROBiosystems. Various species and tags of Siglec-6 proteins. Minimal Batch-to-Batch Variation. Bulks in stock.
First-generation immune checkpoint inhibitors, including anti-CTLA-4 and anti-programmed death 1 (anti-PD-1) antibodies, have led to major clinical progress, yet resistance frequently leads to treatment failure. Thus, new targets acting on T cells are needed. CD33-related sialic acid-binding immunoglobulin-like lectins (Siglecs) are pattern-recognition immune receptors binding to a range of sialoglycan ligands, which appear to function as self-associated molecular patterns (SAMPs) that suppress autoimmune responses. Siglecs are expressed at very low levels on normal T cells, and these receptors were not until recently considered as interesting targets on T cells for cancer immunotherapy. Here, we show an upregulation of Siglecs, including Siglec-9, on tumor-infiltrating T cells from non-small cell lung cancer (NSCLC), colorectal, and ovarian cancer patients. Siglec-9-expressing T cells coexpressed several inhibitory receptors, including PD-1. Targeting of the sialoglycan-SAMP/Siglec pa
TY - JOUR. T1 - Characterization of expression of glycan ligands for Siglec-F in normal mouse lungs. AU - Guo, Jin P.. AU - Brummet, Mary E.. AU - Myers, Allen C.. AU - Na, Ho Jeong. AU - Rowland, Elizabeth. AU - Schnaar, Ronald L.. AU - Zheng, Tao. AU - Zhu, Zhou. AU - Bochner, Bruce S.. PY - 2011/2/1. Y1 - 2011/2/1. N2 - Sialic acid-binding immunoglobulin-like lectin (Siglec)-F, an inhibitory receptor on mouse eosinophils, preferentially recognizes the glycan ligand 69-sulfated sialyl Lewis X, but little is known about the requirements for its lung expression. RT-PCR and immunohistochemistry were used to detect and localize the sulfotransferase keratin sulfate galactose 6-O sulfotransferase (KSGal6ST, alsoknown as carbohydrate sulfotransferase 1; gene name, Chst1) that is putatively required for 6′-sulfated Sialyl Lewis X synthesis. RT-PCR detected the greatest constitutive expression of Chst1 in lung, liver, andspleen tissue.Immunohistochemistry localized the expression of KSGal6ST in lung ...
First-generation immune checkpoint inhibitors, including anti-CTLA-4 and anti-programmed death 1 (anti-PD-1) antibodies, have led to major clinical progress, yet resistance frequently leads to treatment failure. Thus, new targets acting on T cells are needed. CD33-related sialic acid-binding immunoglobulin-like lectins (Siglecs) are pattern-recognition immune receptors binding to a range of sialoglycan ligands, which appear to function as self-associated molecular patterns (SAMPs) that suppress autoimmune responses. Siglecs are expressed at very low levels on normal T cells, and these receptors were not until recently considered as interesting targets on T cells for cancer immunotherapy. Here, we show an upregulation of Siglecs, including Siglec-9, on tumor-infiltrating T cells from non-small cell lung cancer (NSCLC), colorectal, and ovarian cancer patients. Siglec-9-expressing T cells coexpressed several inhibitory receptors, including PD-1. Targeting of the sialoglycan-SAMP/Siglec pathway in ...
Sepsis is the most frequent cause of death in hospitalized patients, and severe sepsis is a leading contributory factor to acute respiratory distress syndrome (ARDS). At present, there is no effective treatment for these conditions, and care is primarily supportive. Murine sialic acid-binding immunoglobulin-like lectin-E (Siglec-E) and its human orthologs Siglec-7 and Siglec-9 are immunomodulatory receptors found predominantly on hematopoietic cells. These receptors are important negative regulators of acute inflammatory responses and are potential targets for the treatment of sepsis and ARDS. We describe a Siglec-targeting platform consisting of poly(lactic-co-glycolic acid) nanoparticles decorated with a natural Siglec ligand, di(α2→8) N-acetylneuraminic acid (α2,8 NANA-NP). This nanoparticle induced enhanced oligomerization of the murine Siglec-E receptor on the surface of macrophages, unlike the free α2,8 NANA ligand. Furthermore, treatment of murine macrophages with these nanoparticles ...
Tumor-infiltrating immune cells are a hallmark of most solid tumors, and the presence of varied immune populations significantly affects clinical outcomes for patients with cancer (1, 2). Historically, tumor-infiltrating immune cells have been viewed as restraining tumor progression (3), but in recent years, it has become more widely appreciated that chronic immune responses play critical roles in promoting tumor progression, metastasis, and resistance to cytotoxic therapies (1). Therefore, understanding the molecular mechanisms by which malignant cells derail antitumor immune responses to favor disease progression is critical to identify potential therapeutic targets. Recently, we reported that selective depletion of tumor-infiltrating macrophages (TAM) by neutralizing colony-stimulating factor-1 (CSF1) or inhibiting CSF1 receptor (CSF1R) activity improves the efficacy of chemotherapy in mammary tumors, in part by instigating antitumor responses by CD8+ T cells (4). Similarly, deficiency in the ...
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
Links to sites outside of Pfizer Medical Information are provided as a resource to the viewer. This third-party website is neither owned nor controlled by Pfizer, and Pfizer does not endorse and is not responsible for the content or services of this site. ...
SIGLEC H, PerCP-eFluor™ 710, clone: eBio440c, eBioscience™ 100μg; PerCP-eFluor™ 710 SIGLEC H, PerCP-eFluor™ 710, clone: eBio440c,...
Prospective, multicenter, uncontrolled cohort study to analyze the efficacy of a risk adapted treatment strategy, including gemtuzumab ozogamicin (GO) d
Siglec-15 serves as a paradigm for several siglecs, including Siglec-14[1], Siglec-16[2] and Siglec-H[3][4], that contain a basic amino acid within the transmembrane domain[5]. This leads to association of these siglecs with a transmembrane adaptor protein containing an immunoreceptor tyrosine based activation motif (ITAM). Siglec-15 is unusual compared to other siglecs that share this paradigm in two respects. Firstly it can associate with two ITAM containing adaptors, DAP12 and DAP10, whereas Siglec-14, Siglec-16, and Siglec-H show a restricted association with DAP12. Siglec-15 is also unusual in having four cysteine residues in the V-set domain predicted to result in an inter-sheet disulfide that is absent from all other known siglecs. These potentially activating siglecs are expressed on myeloid cells and dendritic cells and may be involved in innate responses to pathogen challenge. ...
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Pediatrics . Östergötlands Läns Landsting, Centre of Paediatrics and Gynecology and Obstetrics, Department of Paediatrics in Linköping. ...
A delicate balance between inducers and inhibitors of apoptosis exists in any given cell (37). In cancer cells, including melanoma, this equilibrium is often skewed in favor of survival, with IAPs being predominant (38, 39). Committing melanoma cells to apoptosis, which would be an ideal outcome for most therapies, therefore requires additional stimuli. Inhibition of IAPs for one can restore the balance between survival and death signals, thereby facilitating programmed cell death in melanoma.. Chronic inflammation in the tumor microenvironment of melanoma lesions often leads to elevated levels of TNF-α, at least in part, provided by the tumor-infiltrating immune cells such as macrophages (23-25). Levels of tumor-infiltrating macrophages have been shown to be associated with aggressive disease (40). All melanoma cell lines tested were resistant to treatment with exogenous TNF-α as a single agent. This was in line with previous clinical experiences, where minimal antitumor effect and ...
Siglec-H, 0.5 mg. Siglec-H, or sialic acid binding immunoglobulin-like lectin H, is a CD33 related protein expressed specifically by plasmacytoid dendritic cells or pDCs (1, 2).
This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in participants with acute myeloid leukemia. Immunotherapy with monoclonal antibodies, such as gemtuzumab ozogamicin, may help the bodys immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ...
Activation of monocyte-derived cells occurs at most sites of inflammation and serves as a first line of defense in the immune system by removing foreign objects...
Background: EBUS-TBNA is performed to harvest cytologic and core-biopsy specimens in patients with mediastinal lesions. Rapid cytologic examinations of the sample are expected to increase the diagnostic rates. We studied the value of USB microscope as Rapid On-site Microscopic Evaluation (ROME) of core-biopsy specimens.. Methods: We performed ROME in 20 core-biopsy specimens sampled by EBUS-TBNA. The specimens were divided into five groups according to the microscopic findings. The group I was classified when whitish tumor islets were not found. The group II has one or several tiny suspicious tumor islets. The group III has less than 5 visible tumor islets, the group IV 5 - 10, and the group V more than 10 tumor islets. The ROME was compared with the final pathologic examination. Results: Among 20 specimens, 3 (15%) were in group I, 2 (10%) in group II, 5 (25%) in group III, 7 (35%) in group IV, and 3 (15%) in group V, respectively. When compared with the pathologic examination, clinical ...
Siglec G Mouse anti-Mouse, PerCP-eFluor 710, Clone: SH2.1, eBioscience™ 25μg; PerCP-eFluor 710 Siglec G Mouse anti-Mouse, PerCP-eFluor 710, Clone: SH2.1,...
Polyclonal antibody for Siglec 2/CD22 detection. Host: Rabbit.Size: 100μg/vial. Tested applications: IHC-P. Reactive species: Human. Siglec 2/CD22 information: Molecular Weight: 95348 MW; Subcellular Localization: Cell membrane; Single-pass type I membran
Varje måndag, klockan 14:15 till 16:00, ges seminarier om aktuell forskning på Vi2 i rum 4307, hus 4, Polacksbacken, Uppsala. Ibland ges även extra seminarier vid andra tillfällen än den ovan nämnda tiden. Seminarierna är öppna för alla som är intresserade av ämnet.. ...
PRIMARY OBJECTIVES:. I. To study safety and efficacy single agent Gemtuzumab Ozogamicin (Mylotarg®) as induction therapy for patients with Acute Myeloid Leukemia (AML) who have relapsed after standard treatments or who are not candidates for standard consolidation treatment after Daunorubicin and cytosine arabinoside.. SECONDARY OBJECTIVES:. I. To correlate morbidity and mortality with the use of gemtuzumab (gemtuzumab ozogamicin) to specific subtypes of leukemia.. II. To correlate gemtuzumab response to degree of cluster of differentiation (CD) 33 positivity.. III. To correlate FMS-Related Tyrosine Kinase 3 (FLT 3)/nucleophosmin (NPM) status and CD 33 positivity to gemtuzumab response.. IV. To document incidence of sinusoidal obstruction syndrome with the use of gemtuzumab.. OUTLINE:. Patients receive gemtuzumab ozogamicin intravenously (IV) over 2 hours on days 1 and 15. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.. After completion of study ...
Hepatotoxicity, including life-threatening and sometimes fatal hepatic VOD events, have been reported in patients receiving MYLOTARG as a single agent or as part of a combination chemotherapy regimen [see Adverse Reactions (6)].. In ALFA-0701, VOD events were reported in 6/131 (5%) adult patients during or following treatment with MYLOTARG, or following later hematopoietic stem cell transplantation (HSCT). The median time from the MYLOTARG dose to onset of VOD was 9 days (range: 2-298 days), with 5 events occurring within 28 days of any dose of MYLOTARG and 1 event occurring greater than 28 days after the last dose of MYLOTARG. Three of the 6 VOD events were fatal. VOD was also reported in 2 patients in the control arm of ALFA-0701 after receiving MYLOTARG as a therapy for relapsed AML.. In MyloFrance-1 (MYLOTARG 3 mg/m2 on Days 1, 4 and 7), VOD events were reported in none of the 57 patients during or following treatment, or following HSCT after completion of MYLOTARG treatment.. In AAML0531, ...
Sialic-acid-binding immunoglobulin-like lectins (Siglecs) are members of the Ig superfamily that bind sialic acids in different linkages in a wide variety of glycoconjugates. These membrane receptors are expressed in a highly specific manner, predominantly within the haematopoietic system. The CD33- …
Tumor-associated macrophages (TAMs) are the multifarious group of cells that originate mainly from the peritumoral tissue or bone marrow and can be divided into two main types: M1 and M2. Among them are the infiltrating M1 tumor-associated macrophages present in the early stages of tumorigenesis, which can secrete proinflammatory cytokines and in turn inhibit tumor growth. On the contrary, M2 tumor-associated macrophages are predominant in the late stage of tumor formation. Type II cytokines, which are secreted by them, can promote anti-inflammatory reaction and thus promote tumor growth. However, it remains unclear when M1 tumor-associated macrophages are transformed to M2 tumor-associated macrophages, but tumor hypoxia is currently thought to be associated with such a shift. M2 tumor-associated macrophages secrete many proteases such as cathepsin, cytokines, and an epidermal growth factor. The presence of M2 TAMs make the tumor prone to growth and angiogenesis, which in turn damages other ...
Objectives: To evaluate the impact of myeloid antigen expression on complete remission (CR), event-free survival (EFS), and overall survival (OS) in patients with T-cell acute lymphoblastic leukemia (T-ALL) treated with intensive chemotherapy. Methods: We retrospectively reviewed consecutive patients diagnosed with T-ALL and treated in Sultan Qaboos University Hospital and Royal Hospital in Oman between 2004 and 2010. The diagnosis of T-ALL was established using French-American-British classification or World Health Organization criteria. Patients were considered having myeloid antigen expression if they expressed CD13, CD33, or both (My+ and My-). Results: Of the 39 patients, 38 were included in the study (25 patients with My- and median age of 18.4 years, 13 patients with My+ and median age of 22.0 years). Median follow-up was 12 months. Thirty-two out of the total cohort were eligible for response-rate assessment. Twenty-nine patients (90.6%) achieved CR with one or two courses of ...
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
SAN DIEGO -- Oncologists are re-evaluating gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia, with new results presented here suggesting its 2010 withdrawal from the market may have been prem
ALS researchers from around the world gathered in Berlin, Germany, Dec. 8-10, to report on and discuss the latest research advances in this disease. Daily updates from the symposium are available online at the Web sites of the Motor Neurone Disease Association (MNDA Symposium reports) and ALS Therapy Development Institute (ALS TDI Symposium reports). ...
Siglecs (sialic acid-binding lg-like lectins) are mainly expressed in the immune system. Sn (sialoadhesin) (siglec-1), CD22 (siglec-2) and siglec-15 are well ...
Polyclonal antibody for SIGLEC 4A/MAG detection. Host: Rabbit.Size: 100μg/vial. Tested applications: WB. Reactive species: Human. SIGLEC 4A/MAG information: Molecular Weight: 69069 MW; Subcellular Localization: Membrane; Single-pass type I membrane protei
Abcams Siglec 9 ELISA Kit suitable for Cell culture supernatant, Serum, Plasma in human. Reliably quantify 130 pg/ml of Siglec 9.
TY - CONF. T1 - The Role of Gemtuzumab Ozogamicin in Elderly AML Patients in Complete Remission. AU - Siragusa, Sergio. PY - 2007. Y1 - 2007. N2 - The majority of patients (pts) with acute myeloid leukemia (AML) are diagnosed in their 6th and 7th decade of life. AML in elderly pts is associated with poor response to conventional chemotherapy and limited long-term survival, reflecting a higher incidence multidrug resistance mechanisms, a low bone marrow reserve which may prevent/delay the recovery of hematopoiesis after treatment, and the occurrence of co-morbidities. Gemtuzumab ozogamicin (GO) is an immunoconjugate with a humanized anti-CD33 that after internalization, releases a cytotoxic drug, calicheamicin; ≥80% of AML pts have myeloid blast cells that express the CD33 surface antigen. GO as a single agent has low antileukemic activity (Sievers et al, J Clin Oncol 2001;19:3244-54). However, GO is being used at lower doses in combined chemotherapy regimens as induction or postremission ...
In this study we immunophenotypically differentiate subpopulations of brain macrophages into perivascular macrophages and parenchymal microglia and demonstrate that perivascular macrophages are the major cell productively infected by SIV in the CNS of macaques. Preferential infection of perivascular macrophages in the CNS may account for several important observations concerning infection of the CNS, viral dynamics in the CNS, and the role of the CNS as a viral sanctuary or reservoir.. Although it has not been directly demonstrated, it is generally assumed that lentiviruses enter the CNS by the traffic of infected monocyte/macrophages (64). Our data showing that perivascular macrophages are the major cell type, infected in the brain, support this hypothesis. Studies in chimeric rodents and humans receiving bone marrow indicate that perivascular macrophages are continuously replaced from the circulation (15)(16)(17)(43). The immunophenotype described for perivascular macrophages, ...
R01 AI072265, NIH/NIAID - Bochner (PI). Studies in this grant will explore whether Siglec-8, a molecule selectively expressed by eosinophils and mast cells, can be targeted for both diagnostic and therapeutic purposes in allergic, gastrointestinal and malignant diseases.. Siglecs (sialic acid-binding, immunoglobulin-like lectins) are cell surface proteins found predominantly on leukocytes. Siglec-8 was discovered by us about a decade ago and is selectively expressed on eosinophils and mast cells. Its closest functional paralog in the mouse is Siglec-F, which is also selectively expressed by eosinophils but unfortunately not on mast cells. Both Siglec-8 and Siglec-F preferentially and uniquely recognize the glycan 6-sulfo-sialyl Lewis X (6-sulfo-sLeX) and its non-fucosylated form. Engagement of Siglec-8/-F with antibodies (Abs) and/or artificial ligands causes eosinophil death. Administration of Siglec-F Abs in mouse models of chronic allergic asthma and eosinophilia normalizes eosinophilic ...
Gustave We use F4/80 as a macrophage marker in mice. We have also tried MAC-2. Both work fine on FFPE tissue. Most of our clients ask for the F4/80 marker. We purchase ours from serotec. Liz Elizabeth A. Chlipala, BS, HTL(ASCP)QIHC Manager Premier Laboratory, LLC P.O. Box 18592 Boulder, Colorado 80308 Office: (303) 735-5001 Fax: (303) 735-3540 [email protected] www.premierlab.com Ship to Address: Premier Laboratory University of Colorado MCDB, Room A3B40 Boulder, Colorado 80309 -----Original Message----- From: [email protected] [mailto:[email protected]] On Behalf Of GT Hebert Sent: Monday, July 11, 2005 9:30 AM To: [email protected] Subject: [Histonet] Macrophage marker mouse tissue Hello, I am in need of a good macrophage marker on FFPE tissue. I will be using it on mouse tissue... mainly the heart (but other tissues may be included). So far I have looked into a number of antibodies (CD68, Mac-2) but can never be certain which ...
1O9Z: The Fimbrial Adhesin F17-G of Enterotoxigenic Escherichia Coli Has an Immunoglobulin-Like Lectin Domain that Binds N-Acetylglucosamine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
Metcalfe, H J and Best, A and Kanellos, T and La Radione, R M and Werling, D (2010) Flagellin expression enhances Salmonella accumulation in TLR5-positive macrophages. Developmental and Comparative Immunology, 34 (8). pp. 797-804. ...